JP2020508303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508303A5 JP2020508303A5 JP2019544658A JP2019544658A JP2020508303A5 JP 2020508303 A5 JP2020508303 A5 JP 2020508303A5 JP 2019544658 A JP2019544658 A JP 2019544658A JP 2019544658 A JP2019544658 A JP 2019544658A JP 2020508303 A5 JP2020508303 A5 JP 2020508303A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/074365 WO2018152687A1 (en) | 2017-02-22 | 2017-02-22 | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| CNPCT/CN2017/074365 | 2017-02-22 | ||
| CNPCT/CN2017/088570 | 2017-06-16 | ||
| CN2017088570 | 2017-06-16 | ||
| PCT/CN2018/076940 WO2018153340A1 (en) | 2017-02-22 | 2018-02-22 | Anti-lag-3 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508303A JP2020508303A (ja) | 2020-03-19 |
| JP2020508303A5 true JP2020508303A5 (enExample) | 2020-06-25 |
| JP6929951B2 JP6929951B2 (ja) | 2021-09-01 |
Family
ID=63253327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544658A Active JP6929951B2 (ja) | 2017-02-22 | 2018-02-22 | 抗ｌａｇ−３抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10577421B2 (enExample) |
| EP (1) | EP3389702A4 (enExample) |
| JP (1) | JP6929951B2 (enExample) |
| KR (2) | KR102236259B1 (enExample) |
| CN (1) | CN109475617B (enExample) |
| AU (1) | AU2018226298B2 (enExample) |
| CA (1) | CA3053989C (enExample) |
| IL (1) | IL268734A (enExample) |
| NZ (1) | NZ756678A (enExample) |
| SG (1) | SG11201907561PA (enExample) |
| WO (1) | WO2018153340A1 (enExample) |
| ZA (1) | ZA201905790B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202542197A (zh) * | 2017-07-06 | 2025-11-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| CN110678484B (zh) * | 2018-08-21 | 2022-12-27 | 天境生物科技(杭州)有限公司 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
| JP7177543B2 (ja) * | 2018-08-21 | 2022-11-24 | エービーエル バイオ インコーポレイテッド | 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用 |
| CN110066334B (zh) * | 2019-03-22 | 2020-03-10 | 南京医科大学 | 抗Galectin-3的全人源化单域抗体及应用 |
| CN112010976B (zh) * | 2019-05-29 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗lag3抗体及其用途 |
| CN110320367A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| CA3143242A1 (en) * | 2019-06-14 | 2020-12-17 | Abl Bio Inc. | Bispecific antibody against a-syn/igf1r and use thereof |
| MX2022000456A (es) * | 2019-07-11 | 2022-04-18 | Wuhan Yzy Biopharma Co Ltd | Anticuerpos biespecificos simetricos tetravalentes. |
| CN114206940B (zh) * | 2019-07-23 | 2023-09-22 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗lag-3双特异抗体及其制备方法和应用 |
| CN113004407B (zh) * | 2019-12-20 | 2022-11-11 | 广东菲鹏制药股份有限公司 | Lag3抗体及其应用 |
| CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| CN116162157B (zh) * | 2020-05-19 | 2025-07-01 | 益科思特(北京)医药科技发展有限公司 | 抗新型冠状病毒Spike蛋白抗体及其应用 |
| CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
| CN112062832B (zh) * | 2020-09-24 | 2021-08-03 | 河南赛诺特生物技术有限公司 | Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒 |
| CN114621345B (zh) * | 2020-12-10 | 2022-11-29 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN115490764B (zh) * | 2021-06-18 | 2025-06-03 | 佛山热休生物技术有限公司 | Lgals3的表位肽及所述表位肽与热休克蛋白的复合物 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250198990A1 (en) * | 2022-03-15 | 2025-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Identifying Anti-LAG-3 Agents |
| CN115819595B (zh) * | 2023-01-03 | 2023-05-16 | 上海百英生物科技股份有限公司 | 一种抗lag3纳米抗体及其制备方法与应用 |
| WO2024189628A1 (en) * | 2023-03-16 | 2024-09-19 | Technion Research And Development Foundation Limited | Lag-3 inhibition for enhanced antiviral immune response |
| WO2024196072A1 (ko) * | 2023-03-20 | 2024-09-26 | 경북대학교 산학협력단 | Lag-3에 결합하는 펩타이드 및 이의 용도 |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
| US20250197493A1 (en) * | 2023-12-13 | 2025-06-19 | Eli Lilly And Company | Lag-3 agonist antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| HRP20201113T1 (hr) * | 2013-03-15 | 2020-10-30 | Glaxosmithkline Intellectual Property Development Limited | Vežući proteini protiv lag-3 |
| BR112016012358A2 (pt) * | 2013-12-06 | 2017-09-26 | Dana Farber Cancer Inst Inc | peptídios terapêuticos |
| TWI777174B (zh) * | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CA2993177A1 (en) * | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| HUE055207T2 (hu) * | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
-
2018
- 2018-02-22 US US16/069,487 patent/US10577421B2/en active Active
- 2018-02-22 KR KR1020197014275A patent/KR102236259B1/ko active Active
- 2018-02-22 EP EP18733152.5A patent/EP3389702A4/en not_active Withdrawn
- 2018-02-22 AU AU2018226298A patent/AU2018226298B2/en active Active
- 2018-02-22 SG SG11201907561PA patent/SG11201907561PA/en unknown
- 2018-02-22 CN CN201880000932.2A patent/CN109475617B/zh active Active
- 2018-02-22 NZ NZ756678A patent/NZ756678A/en unknown
- 2018-02-22 KR KR1020187022954A patent/KR102144317B1/ko active Active
- 2018-02-22 CA CA3053989A patent/CA3053989C/en active Active
- 2018-02-22 WO PCT/CN2018/076940 patent/WO2018153340A1/en not_active Ceased
- 2018-02-22 JP JP2019544658A patent/JP6929951B2/ja active Active
-
2019
- 2019-08-15 IL IL26873419A patent/IL268734A/en unknown
- 2019-09-02 ZA ZA2019/05790A patent/ZA201905790B/en unknown
- 2019-11-18 US US16/687,387 patent/US11414485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508303A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PH12021500002A1 (en) | ANTIBODY-SIRPa ANTIBODY | |
| JP2024175003A5 (enExample) | ||
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2015534982A5 (enExample) | ||
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2019536806A5 (enExample) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| IL296682B1 (en) | Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| JP2015508762A5 (enExample) | ||
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2010536384A5 (enExample) | ||
| AR086579A1 (es) | Proteinas de union a antigeno | |
| JP2006512899A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| JP2010516229A5 (enExample) | ||
| JP2011518125A5 (enExample) |